Search Results
262 Results for 'Therapeutics & Vaccines'
PAGE 3 OF 11
Technology
A ‘Humanized’ MDCK Cell Line For the Efficient Isolation and Amplification of Seasonal Human Influenza Viruses
Most influenza vaccines are produced in embryonated chicken eggs, but increasingly influenza vaccines are produced in other systems. MDCK (Madin-Darby Canine Kidney) cells are one of two mammalian cel...
Learn More
Learn More
Yoshihiro Kawaoka, Kosuke Takada, Masaki Imai | P180301US04
Technology
Ph-Responsive Polymer–Antibiotic Conjugate For Enhanced Antimicrobial Efficacy
Provided herein are polymer-drug conjugates with enhanced antibacterial efficacy. These conjugates include a polymer comprising a plurality of masked cationic functional groups and an antibiotic drug ...
Learn More
Learn More
Shaoqin Gong, Mingzhou Ye | P200087US02
Technology
COVID-19 Vaccine
Provided herein are antigenic peptides comprising the SARS-CoV-2 spike protein receptor binding domain (CRBD) polypeptide or portions thereof, linked to a non-catalytic, nontoxic tetanus toxin varia...
Learn More
Learn More
Joseph Barbieri, Eric Johnson, Sabine Pellett, William Tepp, Amanda Przedpelski | P200268US03
Technology
RSV Virus-Like Particles And Methods Of Use Thereof
The present disclosure relates to vims-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial vims (RSV) infection. Specifically, the disclosure provides vi...
Learn More
Learn More
Elizabeth Wright, Larry Anderson, Binh Ha | P200021US02
Technology
2-methylene-19-nor Vitamin D2 Compounds
2-Methylene-19-nor-24(S) and 24(R) derivatives of 1α,25-dihydroxyvitamin D2 are disclosed. These compounds are characterized by minimal bone calcium mobilization activity and relatively high intestin...
Learn More
Learn More
Hector DeLuca, Sumithra Gowlugari, Rafal Sicinski | P02026US
Technology
Influenza M2 Protein Mutant Viruses As Influenza Live Attenuated Vaccines
A method to prepare recombinant influenza viruses comprising a mutant M2 protein which has a deletion of two or more residues in the cytoplasmic tail and is attenuated in vivo, is provided, as well th...
Learn More
Learn More
Yoshihiro Kawaoka, Tokiko Watanabe | P07509US
Technology
Once-A-Week Administration Of 25-Hydroxy Vitamin D3 To Sustain Elevated Steady-State Pharmacokinetic Blood Concentration
An oral dosage form comprising a single dose of 25-hydroxy-vitamin D3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and ...
Learn More
Learn More
Hector DeLuca, Lori Plum, Margaret Clagett-Dame | P08138US02
Technology
2-methylene-(20s,25r)-19,26-dinor-vitamin D Analogs
This invention discloses 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25R)-19,26-dinor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This comp...
Learn More
Learn More
Hector DeLuca, Lori Plum, Margaret Clagett-Dame, Grazia Chiellini, Pawel Grzywacz | P08090US
Technology
Reversible Natural Product Glycosyltransferase-catalyzed Reactions, Compounds And Related Methods
The present invention relates to methods of use of glycosyltransferases and related compounds. The invention exploits the reversibility of glycosyltransferases to generate new sugars, unnatural biomol...
Learn More
Learn More
Jon Thorson, Byron Griffith, Changsheng Zhang | P06427US
Technology
Methods For Preventing And Attenuating Hyperphosphatemia
It is disclosed here a method for reducing phosphate absorption in a human or non-human animal subject wherein the subject consumes a diet containing phytic acid or phytate and either has or is at ris...
Learn More
Learn More
Mark Cook, Keith Crawford, Erica Hellestad, Martin Petkovich, Christian Helvig | P06481US
Technology
Compositions And Methods For Treating Hyperphosphatemia In Humans
A method for reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia is disclosed. The method includes the step of administerin...
Learn More
Learn More
Mark Cook, Keith Crawford, Erica Hellestad, Christian Helvig, Martin Petkovich | P07020US
Technology
2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin D3 And Uses Thereof
This invention relates to vitamin D compounds, and more particularly to 2-methylene-1 α,25-dihydroxy-18,19,21-trinorvitamin D3 (DJ-55) and to pharmaceutical formulations that include this compound. T...
Learn More
Learn More
Hector DeLuca, Rafal Barycki, Lori Plum, Margaret Clagett-Dame | P06327US
Technology
2-methylene-1alpha-hydroxy-18,19,21-trinorvitamin D3 Analogs And Uses Thereof
This invention relates to vitamin D compounds, and more particularly to 2-methylene-1α-hydroxy-18,19,21-trinorvitamin D3 (SX-99) and to pharmaceutical formulations that include this compound. The inv...
Learn More
Learn More
Hector DeLuca, Rafal Barycki, Lori Plum, Margaret Clagett-Dame | P06328US
Technology
2-methylene-19-nor-(23s)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone And 2-methylene-19-nor-(2
The invention provides 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (“GC-3”), 2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (“HLV”), and re...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Pawel Grzywacz, Grazia Chiellini | P05291US
Technology
19,26,27-trinor-1alpha,25-dihydroxyvitamin D3 Compounds
This invention relates to vitamin D compounds, and more particularly to 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds such as 2α-methyl-19,26,27-trinor-(20S)-1α,25-dihydroxyvitamin D3 (“P...
Learn More
Learn More
Hector DeLuca, Lori Plum, Pawel Grzywacz, Margaret Clagett-Dame | P05370US
Technology
Use Of Botulinum Toxin For The Treatment Of Hypervolemic Lip Deformity (lip Ectropion)
The present invention uses pharmaceutical preparations of Botulinum toxin to induce neurogenic atrophy to alter muscle volume and subsequently, facial contour. Reduction in lip volume is accomplished ...
Learn More
Learn More
Gary Borodic | P05407US
Technology
17,20(z)-dehydro Vitamin D Analogs And Their Uses
This invention discloses 17,20(Z)-dehydro vitamin D analogs, and specifically 17(Z)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibi...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Bulli Padmaja Tadi | P06097US
Technology
17,20(e)-dehydro Vitamin D Analogs And Their Uses
This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibi...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Bulli Padmaja Tadi | P06117US
Technology
Metabolic-based Methods For Modulating Gene Expression
This invention provides methods for modulating cellular gene expression for genes operably linked to an NRSE element that is recognized by an NRSF transcriptional repressor, by changing the concentrat...
Learn More
Learn More
Thomas Sutula, Avtar Roopra, Barry Schoenike | P05137US
Technology
2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol And Its Uses
This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibit...
Learn More
Learn More
Hector DeLuca, Lori Plum, Rafal Sicinski, Margaret Clagett-Dame | P05163US
Technology
Compounds And Methods For Treating Seizure Disorders
This invention provides methods for alleviating paroxysmal disorders in an animal, particularly epilepsy, by modulating glycolysis in brain cells.
Learn More
Learn More
Thomas Sutula, Avtar Roopra, Steven Kriegler, Carl Stafstrom | P04134US
Technology
Selection Of Patients With Increased Responsiveness To Botulinum Toxin
Botulinum toxin has been shown to be useful for the treatment of pain when administered for cervical dystonia. Given efficacy for pain relief in regional dystonia, further expanded applications have i...
Learn More
Learn More
Gary Borodic | P05052US
Technology
Treatment Of Sinusitis Related Chronic Facial Pain And Headache With Botulinum Toxin Injections
The present invention provides methods for treating sinus-evoked headaches using botulinum toxin injected or applied in multiple subcutaneous locations over divisions of the trigeminal nerve in soft t...
Learn More
Learn More
Gary Borodic, Martin Acquadro | P05053US
Technology
Composition For Therapeutic And Cosmetic Botulinum Toxin
This invention relates to a composition of botulinum based pharmaceuticals used for therapeutic and cosmetic treatment. This invention offers an improvement on the prior art by eliminating the potenti...
Learn More
Learn More
Gary Borodic | P05055US
Technology
Improved Pharmaceutical Botulinum Toxin Compositions
Botulinum toxin, a well know systemic poison, produces favorable therapeutic effect by virtue of regionally attaching to nerves within the myoneural junction and possibly other tissues in a target reg...
Learn More
Learn More
Gary Borodic | P05057US